文献速递炎症性肠病

非靶向粪便代谢组学用于发现炎症性肠病的生物标志物和治疗靶点

Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases.
PubMed 文献 · Gut · 2024-10-07

本文综述了代谢组学在炎症性肠病(IBD)研究中的贡献,重点关注粪便代谢组学。短链脂肪酸、色氨酸代谢物和胆汁酸等代谢物与IBD相关,文章讨论了这些代谢物对IBD预后和治疗干预的意义,并展望了代谢组学研究的未来方向。

要点

  • 肠道微生物产生的代谢物是微生物与宿主免疫或代谢相互作用的重要机制。
  • 短链脂肪酸、色氨酸代谢物和胆汁酸等代谢物与IBD相关。
  • 粪便代谢组学有助于发现IBD的生物标志物和治疗靶点。

核心结论

  • 代谢组学研究,尤其是粪便代谢组学,对发现IBD的生物标志物和治疗靶点具有贡献。

研究设计与样本

  • 本文为近期进展综述,聚焦于粪便代谢组学在IBD领域的研究。

主要发现

  • 短链脂肪酸、色氨酸代谢物和胆汁酸等代谢物与IBD相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The gut microbiome has been recognised as a key component in the pathogenesis of inflammatory bowel diseases (IBD), and the wide range of metabolites produced by gut bacteria are an important mechanism by which the human microbiome interacts with host immunity or host metabolism. High-throughput metabolomic profiling and novel computational approaches now allow for comprehensive assessment of thousands of metabolites in diverse biomaterials, including faecal samples. Several groups of metabolites, including short-chain fatty acids, tryptophan metabolites and bile acids, have been associated with IBD. In this Recent Advances article, we describe the contribution of metabolomics research to the field of IBD, with a focus on faecal metabolomics. We discuss the latest findings on the significance of these metabolites for IBD prognosis and therapeutic interventions and offer insights into the future directions of metabolomics research.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Vich Vila A, Zhang J, Liu M, et al. Untargeted faecal metabolomics for the discovery of biomarkers and treatment targets for inflammatory bowel diseases. Gut. 2024. PMID: 39002973. doi:10.1136/gutjnl-2023-329969

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。